Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The Basics What is Tirzepatide
Even if the needle looks clean, the tip becomes dull after a single use
#CiplaAt90 #CaringforLife Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
Atherosclerosis, one of the main risk factors of CVD, consists of the initial endothelial cell injury followed by lipoprotein deposition, inflammatory reaction, and smooth muscle cell cap formation 2
Ideal candidates are not currently pregnant or breastfeeding and may be at risk for or currently managing weight-related health issues
